Haemonetics Corp HAE
Haemonetics Corp (NYSE: HAE) is a hematology medical device company.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| NexSys PCS Plasma Collection System (Persona PLUS) | plasma collection | unclear | NA_NON_THERAPEUTIC |
| VASCADE / VASCADE MVP XL vascular closure | vascular access site closure | unclear | NA_NON_THERAPEUTIC |
| PerQseal Elite large bore closure | large bore vessel closure (TAVR, EVAR) | unclear | NA_NON_THERAPEUTIC |
| TEG 6s hemostasis analyzer | hemostasis assessment | unclear | NA_NON_THERAPEUTIC |
| Cell Saver Elite+ | intraoperative autotransfusion | unclear | NA_NON_THERAPEUTIC |
| ensoETM esophageal protection | esophageal cooling during RF ablation | unclear | NA_NON_THERAPEUTIC |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other hematology companies
- Cerus Corp CERS
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.